Jagannath Discusses Building on the Biology of Multiple Myeloma

Understanding the proliferation of malignant myeloma cells can only be discerned by going back to the biology of the disease, explained Sundar Jagannath, MD, and greater understanding of a patient’s cytogenetics may compound the success seen with chemotherapy and novel adoptive cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapy.

“At the moment, the science is not advanced enough to tailor therapy according to the genetic abnormality. That is our next major goal in clinical research,” said Jagannath. “Understanding how to tailor therapy according to the risk status, genetic nature, or the immune composition of the patient’s bone marrow microenvironment could be studied better,” he added.

In an interview with OncLive® during the 2018 State of the Science Summit™ on Multiple Myeloma, Jagannath, director of the Multiple Myeloma program and professor of Medicine at the Tisch Cancer Institute, Mount Sinai Health System, provided insight into the biology of multiple myeloma.

Read more at: https://www.onclive.com/web-exclusives/jagannath-discusses-building-on-the-biology-of-multiple-myeloma